Theseus Pharmaceuticals to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Theseus Pharmaceuticals (NASDAQ: THRX), a clinical-stage biopharmaceutical company, is set to participate in two upcoming virtual investor conferences. The events include the 22nd Annual Needham Virtual Healthcare Conference on April 20, 2023, at 8:45am ET, and the Stifel 2023 Virtual Targeted Oncology Days on April 26, 2023, at 12:00pm ET. Interested investors can access live webcasts on the company's investor relations website, which will be archived for 30 days post-conference. Theseus focuses on developing targeted therapies for cancer patients, including its lead product candidate, THE-630, designed to treat advanced gastrointestinal stromal tumors (GIST). Other projects include THE-349, aimed at non-small cell lung cancer, and a BCR-ABL inhibitor for chronic myeloid leukemia.

CAMBRIDGE, Mass., April 11, 2023 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) ("Theseus"), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies, today announced that the company will participate virtually in the following upcoming investor conferences:

Event: 22^nd Annual Needham Virtual Healthcare Conference
Fireside Chat Date / Time: Thursday, April 20^th at 8:45am ET

Event: Stifel 2023 Virtual Targeted Oncology Days
Fireside Chat Date / Time: Wednesday, April 26^th at 12:00pm ET

Live webcasts will be available in the Events section of the company's investor relations website at ir.theseusrx.com and archived for 30 days following the presentation.

About Theseus Pharmaceuticals, Inc.
Theseus is a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development, and commercialization of transformative targeted therapies. Theseus is working to outsmart cancer resistance by developing pan-variant tyrosine kinase inhibitors (TKIs) to target all classes of cancer-causing and resistance mutations that lead to clinically relevant variants in a particular protein in a given type of cancer. Theseus' lead product candidate, THE-630, is a pan-variant KIT inhibitor for the treatment of patients with advanced gastrointestinal stromal tumors (GIST), whose cancer has developed resistance to earlier lines of kinase inhibitor therapy. Theseus is also developing THE-349, a fourth-generation, selective epidermal growth factor receptor (EGFR) inhibitor for C797X-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer (NSCLC), and a pan-variant BCR-ABL inhibitor for the treatment of relapsed/refractory chronic myeloid leukemia (CML) and newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). For more information, visit www.theseusrx.com.

Media Contact
Christen Baglaneas
Director, Corporate Communications & Investor Relations
Theseus Pharmaceuticals
857-706-4993
christen.baglaneas@theseusrx.com

Investor Contact
Josh Rappaport
Stern Investor Relations
212-362-1200
josh.rappaport@sternir.com

View original content:https://www.prnewswire.com/news-releases/theseus-pharmaceuticals-to-participate-in-upcoming-investor-conferences-301793838.html

SOURCE Theseus Pharmaceuticals

FAQ

What investor conferences will Theseus Pharmaceuticals participate in April 2023?

Theseus Pharmaceuticals will participate in the 22nd Annual Needham Virtual Healthcare Conference on April 20, 2023, and the Stifel 2023 Virtual Targeted Oncology Days on April 26, 2023.

What is the significance of THRX's participation in these conferences?

Participation in these conferences provides an opportunity for Theseus Pharmaceuticals to present their advancements in cancer therapies to potential investors and stakeholders.

What product does THRX focus on for treating gastrointestinal stromal tumors?

Theseus Pharmaceuticals' lead product candidate, THE-630, is a pan-variant KIT inhibitor aimed at treating advanced gastrointestinal stromal tumors (GIST).

Which other cancer treatments is Theseus Pharmaceuticals developing?

In addition to THE-630, Theseus is developing THE-349, an EGFR inhibitor for non-small cell lung cancer, and a pan-variant BCR-ABL inhibitor for chronic myeloid leukemia.

How can I access the webcasts for THRX's investor conferences?

Live webcasts for Theseus Pharmaceuticals' investor conferences will be available on their investor relations website and archived for 30 days after the events.